Who are CHF1535 200/6 µg pMDI's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chf1535-200-6-g-pmdi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CHF1535 200/6 µg pMDI — Competitive Intelligence Brief

CHF1535 200/6 µg pMDI (CHF1535 200/6 µg pMDI) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ICS/LABA combination (Inhaled Corticosteroid/Long-Acting Beta-2 Agonist). Area: Respiratory/Pulmonology.

phase 3 ICS/LABA combination (Inhaled Corticosteroid/Long-Acting Beta-2 Agonist) Glucocorticoid receptor (beclomethasone); Beta-2 adrenergic receptor (formoterol) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

CHF1535 200/6 µg pMDI (CHF1535 200/6 µg pMDI) — Chiesi Farmaceutici S.p.A.. CHF1535 is a fixed-dose combination of beclomethasone dipropionate (ICS) and formoterol (LABA) that reduces airway inflammation and improves bronchial smooth muscle relaxation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CHF1535 200/6 µg pMDI TARGET	CHF1535 200/6 µg pMDI	Chiesi Farmaceutici S.p.A.	phase 3	ICS/LABA combination (Inhaled Corticosteroid/Long-Acting Beta-2 Agonist)	Glucocorticoid receptor (beclomethasone); Beta-2 adrenergic receptor (formoterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ICS/LABA combination (Inhaled Corticosteroid/Long-Acting Beta-2 Agonist) class)

Chiesi Farmaceutici S.p.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CHF1535 200/6 µg pMDI — Competitive Intelligence Brief. https://druglandscape.com/ci/chf1535-200-6-g-pmdi. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab